Stocks · News reference
Novartis Pharma AG, a subsidiary of Novartis AG, has entered into a strategic collaboration with Dren Bio to discover and develop bispecific antibodies for cancer treatment.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
RBC Capital Markets has increased its price target for Novartis AG from CHF120 to CHF130 while maintaining a Sector Perform rating.